Clinical Research Directory

Inclusion Criteria: Adult patients presenting with spontaneous intraparenchymal hemorrhage within 72 hours of symptom onset and qualifying for at least one of the following categories: i. history of symptomatic coronary, peripheral and/or carotid artery disease (severe atherosclerotic vascular disease), or ii. visualized extracranial cervical/intracranial atherosclerotic disease causing any degree of stenosis/occlusion or presence of aortic arch plaque with maximum thickness ≥1 mm (moderate atherosclerotic vascular disease), or iii. two or more risk factors including: age 60 years or older, hypertension, dyslipidemia, diabetes mellitus, chronic kidney disease (eGFR: 15-50mL/min), history of ischemic stroke or current smoking (mild atherosclerotic vascular disease). Exclusion Criteria: * secondary causes of ICH (such as trauma, macrovascular anomalies, neoplasms or bleeding diathesis) * ICH volume more than 60ml in the last imaging scan prior to consent * Glasgow Coma Scale (GCS) score less than 7 or being intubated at the time of consent * inflammatory bowel disease or chronic diarrhea * cirrhosis or severe hepatic dysfunction * renal insufficiency (eGFR\<15mL/min) * concurrent or planned treatment with strong CYP3A4 inhibitors (atazanavir, clarithromycin, darunavir/ritonavir, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, tipranavir/ritonavir) or P-gp inhibitors (cyclosporine, ranolazine) * pregnancy or breast-feeding * known allergy or sensitivity to colchicine * a strong indication for colchicine where assignment to placebo is deemed unacceptable * estimated life expectancy less than 6 months at the time of enrollment, and * inability to adhere to study procedures